PharmatecaPharmatecaФарматека2073-40342414-9128Bionika Media278850ArticlesСтатьиSEXUAL REHABILITATION OF PATIENTS AFTER BRACHYTHERAPY FOR LOCALIZED PROSTATE CANCERСЕКСУАЛЬНАЯ РЕАБИЛИТАЦИЯ БОЛЬНЫХ ПОСЛЕ БРАХИТЕРАПИИ ПО ПОВОДУ ЛОКАЛИЗОВАННОГО РАКА ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫGamidovSafail oglyГамидовСафаил оглы

ГОУ ВПО РГМУ, Москва

ChepurovAleksandr KonstantinovichЧепуровАлександр Константинович

ГОУ ВПО РГМУ, Москва

PerovRoman AleksandrovichПеровРоман Александрович

ГОУ ВПО РГМУ, Москва

GamidovS IChepurovA KPerovR AГОУ ВПО РГМУ, Москва20032011186NO6 (2011)№6 (2011)677123022023Copyright ©; 2011, Bionika MediaCopyright ©; 2011, ООО «Бионика Медиа»2011Bionika MediaООО «Бионика Медиа»https://journals.eco-vector.com/2073-4034/article/view/278850

Increased number of relatively young men who underwent brachytherapy for localized prostate cancer has led to increase the relevance of the question of quality of life for these patients. Erectile dysfunction (ED) is one of the major factors adversely affecting the quality of life. The high prevalence of ED after brachytherapy and the lack of a unified approach to safe and effective therapy for this condition dictate the need for more in-depth study of the problem, which is extremely important from the standpoint of optimizing the treatment of this category of patients.

Увеличение числа относительно молодых мужчин, перенесших брахитерапию локализованного рака предстательной железы, привело к повышению актуальности вопроса о качестве жизни этих больных. Одним из основных факторов, неблагоприятно влияющих на качество жизни, является эректильная дисфункция (ЭД). Высокая распространенность ЭД после брахитерапии, отсутствие единого подхода к эффективной и безопасной терапии этого состояния диктуют необходимость более углубленного изучения данной проблемы, что чрезвычайно важно с точки зрения оптимизации лечения указанной категории пациентов.

erectile dysfunctionbrachytherapyprostate cancerphosphodiesterase-5 inhibitorsэректильная дисфункциябрахитерапиярак предстательной железыингибиторы фосфодиэстеразы-5Parker SL, Tong T, Bolden S, et al. Cancer statistics 1996. CA Cancer J Clin 1996;46:5.Stone NN, Stock RG. Complications Following Permanent Prostate Brachytherapy. Eur Urol 2002;41:427-33.Iversen P, Newling D, Kirby R, et al. Sexual function: Quality of life issues in patients with locally advanced non-metastatic prostate cancer. Eur Urol Suppl 2002;1:26-32.Litwin MS, Flanders SC, Pasta DJ, et al. Sexual functions and bother after radical prostatectomy or radiation for prostate cancer: multivariate quality of life analysis from CAPSURE. Cancer of the prostate strategic. Urologic Research Endeavor. Urology 1999;54:503.Ofman US. Sexual quality of life in men with prostate cancer. Cancer 1995;75:1949.Critz FA, Tarlton RS, Holiday DA. Prostate-specific antigen-monitored combination radiotherapy for patients with prostate cancer: 125I implant followed by external-beam radiation. Cancer 1995;75:2383.Dattoli M, Wallner K, Sorace R, et al. 103Pd brachytherapy and external beam irradiation for clinically localized high-risk prostatic carcinoma. Int J Radiat Oncol Biol Phys 1996;35:1-5.Kaye KW, Olson DJ, Payne JT. Detailed preliminary analysis of iodine-125 implantation for localized prostate cancer using percutaneous approach. J Urol 1995;153:1020-25.Wallner K, Roy J, Harrison L. Tumor control and morbidity following transperineal iodine-125 implantation for stage T1/T2 prostatic carcinoma. J Clin Oncol 1996;14:449-53.Kao J, Stock RG, Stone NN. Long-term erectile function following real-time ultrasound-guided brachytherapy for prostate cancer. J Urol 2000;163:1276.Incrocci L, van der Wielen GJ. Erectile Function after Prostate Brachytherapy. Eur Urol 2007;52:282-283.Mabjeesh N, Beri A, Stenger A, et al. Erectile function after permanent prostate brachytherapy: Long-term results. Eur Urol Suppl 2004;3:33.Merrick GS, Galbreath RW, Butler WM, et al. Erectile Function After Prostate Brachytherapy. J Urol 2006;175:959-60.Seftel AA. Erectile Function After Prostate Brachytherapy. J Urol 2005;174:2299-300.Anderson RL, Merrick GS, Butler WM, et al. Erectile function following permanent prostate brachytherapy: Results of two prospective randomized trials. Int J Radiat Oncol Biol Phys 2004;60:453.Schiff J, Bar-Chama N, Cesaretti J, et al. Neo-adjuvant and adjuvant hormone suppression therapy adversely impacts erectile function after brachytherapy. Fertility and Sterility 2006;86:28-29.Merrick GS, Butler WM, Galbreath RW, et al. Erectile function after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2002;52:893-902.Stone NN, Cesaretti JA, Rosenstein B, et al. Do high radiation doses in locally advanced prostate cancer patients treated with 103Pd implant plus external beam irradiation cause increased urinary, rectal, and sexual morbidity? Brachytherapy 2010;9(2):114-48.Losa A, Nava L, Maga T, et al. Quality of life and sexual function after palladium 103 prostate brachytherapy. Eur Urol Suppl 2002;1:46.Rotella DP. Phosphodiesterase 5 inhibitors: current status and potential applications. Nat Rev Drug Discov 2002;1:674-82.Canada AL, Neese LE, Sui D, et al. Pilot intervention to enhance sexual rehabilitation for couples after treatment for localized prostate carcinoma. Cancer 2005;104:2689-700.Pahlajani G, Raina R, Phillippi A, et al. Early Intervention with PDE-5 Inhibitors Following Prostate Brachytherapy Improves Subsequent Erectile Function. Int J Radiat Oncol Biol Phys 2008;72:503.Shemtov OM, Radomski SB, Crook J. Success of sildenafil for erectile dysfunction in men treated with brachytherapy or external beam radiation for prostate cancer. Can J Urol 2004;11:2450-55.Montorsi F, Maga T, Strambi L, et al. Sildenafil taken at bedtime significantly increase nocturnal erection results of a placebo-controlled study. J Urol 2000;56:906-911.Montorsi F, Salonia A, Briganti A, et al. Vardenafil for the treatment of erectile dysfunction: a critical review of the literature based on personal clinical experience. Eur Urol 2005;47:612-21.Merrick GS, Butler WM, Lief JH, et al. Efficacy of sildenafil citrate in prostate brachytherapy patients with erectile dysfunction. Urol 1999;53:1112-16.Montorsi F, Verheyden B, Meuleman E, et al. Long-term safety and tolerability of tadalafil in the treatment of erectile dysfunction. Eur Urol 2004;45:339-44.Pahlajani G, Raina R, Jones JS, et al. Early intervention with phosphodiesterase-5 inhibitors after prostate brachytherapy improves subsequent erectile function. BJU Int 2010:12.Incrocci L, Slagter C, Slob AK, et al. A randomized, double-blind, placebo-controlled, cross-over study to assess the efficacy of tadalafil (Cialis®) in the treatment of erectile dysfunction following three-dimensional conformal external-beam radiotherapy for prostatic carcinoma. Int J Radiat Oncol Biol Phys 2006;66(Suppl):38-9.Park JL, Cesaretti JA, Kao J, et al. Vardenafil is more efficacious than tadalafil for patient's who requested an alternative to sildenafil following prostate brachytherapy. Int J Radiat Oncol Biol Phys 2006;3(66):540.Rosenberg MT, Adams PL, McBride TA, et al. Improvement in duration of erection following phosphodiesterase type 5 inhibitor therapy with vardenafil in men with erectile dysfunction: the ENDURANCE study. Int J Clin Pract 2009;63:27-34.Peltier A, van Velthoven R, Roumeguare T. Current management of erectile dysfunction after cancer treatment. Curr Opin Oncol 2009;21(4):303-09.Nehra A, Blute ML, Barrett DM, et al. Rationale for combination therapy of intraurethral prostaglandin E (1) and sildenafil in the salvage of erectile dysfunction patients desiring noninvasive therapy. Int j Impot Res 2002;14:38-42.Brock G, Tu LM. Return of spontaneous erection during long-term intracavernosal alprostadil (Caverject) treatment. Urol 2001;57:536-41.